The Bottleneck in Genomics: How Automated Electrophoresis Keeps NGS Workflows Viable

Automated Capillary Electrophoresis for DNA and RNA Analysis

In any high-throughput genomics facility, the bottleneck is rarely the sequencer itself. It is the quality control step that sits between library preparation and sequencing — the moment when fragment size, concentration, and purity must be verified. The Agilent Fragment Analyzer Systems automate this process, replacing manual gel electrophoresis with parallel capillary electrophoresis that processes 12 to 96 samples per run.

The core technology is straightforward: multiple samples are injected into parallel capillaries and separated by size under an electric field. The instrument then generates precise sizing and quantification data for DNA, RNA, and NGS library fragments. A full run completes in under an hour, which is significant when a sequencing facility may process hundreds of libraries daily and cannot afford delays in QC.

What distinguishes an automated system from its manual predecessor is not just speed but reproducibility. In a manual gel, operator technique introduces variability. The Fragment Analyzer removes that variable, delivering consistent electrophoretic separation across runs. For applications like cell-free DNA analysis or RNA integrity assessment, where fragment profiles directly inform clinical decisions, this consistency is non-negotiable.

The instrument’s throughput — 12 to 96 samples per run — maps directly to the operational logic of a modern genomics lab. Smaller labs may run a single plate of 12; larger facilities batch 96 samples to align with plate-based library preparation workflows. The system slots into an existing infrastructure of liquid handlers, thermal cyclers, and sequencers, acting as the gatekeeper that ensures only properly sized libraries proceed to expensive sequencing runs.

From a procurement perspective, the Fragment Analyzer is a capital investment that pays for itself by reducing failed sequencing runs. Each failed run consumes reagents, flow cells, and instrument time — costs that quickly exceed the price of QC equipment. Facilities that process clinical samples or commercial NGS services treat this instrument as standard equipment, not an optional add-on.

China’s role in this supply chain is dual. The country is both a major consumer of such instruments, driven by its expanding sequencing capacity, and a growing manufacturer of capillary electrophoresis consumables and reagents. As domestic firms develop competing platforms, the pressure on pricing and support models increases. For now, Agilent’s installed base in Chinese genomics facilities remains substantial, but the market is watching for localization of both hardware and supply chains.

The quiet reality is that the most critical instrument in a sequencing lab may not be the one that reads DNA, but the one that checks the work before the read begins. Automation of that check is what turns a workflow into a production line.

Why it matters:
For labs scaling NGS throughput, the cost of a single failed sequencing run can exceed the price of a QC instrument. Automated capillary electrophoresis reduces that risk while enabling consistent, auditable quality control. For suppliers, the opportunity lies in consumables and service contracts that accompany every installed system.

View Product →